Before the relative value of a drug can be determined, one must first consider how value is defined by the patient. Dr. Benson and Ms. McClure respond to a viewpoint by Roger Longman, MA.
Roger Longman, MA, offers a perspective on how we can overcome comparative effectiveness research and bring a greater understanding on which drugs work best.
The Use of Risk-Sharing Agreements to Manage Costs, Mitigate Risk, and Improve Value for Pharmaceutical Products
The authors review the types of risk-sharing agreements that have been implemented to date.
Clinical pathways are intended to be used by a multidisciplinary health care team in order to achieve the Triple Aim of healthcare reform.
The Use of Incremental Cost-Effectiveness Ratio Thresholds in Health Technology Assessment Decisions
Cost-effectiveness analysis is used to assess the costs and outcomes of health care interventions in order to arrive at an overall valuation for those options.
The debate continues to rage over the current cost of cancer care and the value that these drugs bring to patients.
Dr. David R. Henderson and Charle L. Hooper offer another perspective on healthcare reform.
Introducing Journal of Clinical Pathways (JCP) – a new peer-reviewed publication that will serve as a forum for the pursuit of attaining quantifiable value in healthcare.
Journal of Clinical Pathways is proud to announce the members of its Editorial Advisory Board.